Key result
EECP increases coronary flow reserve ~26% vs control in coronary microvascular disease.
Why the study?
The outcomes of enhanced external counterpulsation among coronary microvascular disease patients were not well established.
Does enhanced external counterpulsation improve coronary flow reserve and quality of life in patients with coronary microvascular disease?
RCT (n=83)
Single-blind
Randomized
No
Does enhanced external counterpulsation improve coronary flow reserve and quality of life in patients with coronary microvascular disease?
Absolute Event Rate: 2.34% vs 1.85%
p-value: p=<0.05
A 4-week EECP program may improve coronary flow reserve, endothelial function, and angina symptoms in patients with coronary microvascular disease.
OBJECTIVES: To investigates the outcomes of enhanced external counterpulsation (EECP) among coronary microvascular disease (CMD) patients. METHODS: Coronary microvascular disease patients were separated into the EECP (n=41) and control cohorts (n=42). Prior to and following the 4-week EECP program, coronary flow reserve (CFR) was recorded using transthoracic Doppler echocardiography. The serum endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1) contents were analyzed by ELISA. Quality of life (QoL) was assessed by the Seattle Angina Questionnaire (SAQ) and the Canadian Cardiovascular Society (CCS) angina class. RESULTS: <0.05). Endothelin-1 was strongly diminished whereas eNOS was considerably upregulated in the EECP cohort. EECP also enhanced patients' SAQ scores and decreased the CCS angina class. CONCLUSION: Enhanced external counterpulsation may improve CFR and enhance the CMD patient QoL.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted an RCT in Coronary microvascular disease (n=83). Enhanced external counterpulsation vs. Control (standard medication) was evaluated on Coronary flow reserve (CFR) at 4 weeks (p=<0.05). Enhanced external counterpulsation significantly increased coronary flow reserve compared to control (2.34 vs 1.85, p<0.05) after four weeks in patients with coronary microvascular disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: